{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:25:57Z","timestamp":1790641557255,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.lpm.2024.104264","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T17:08:29Z","timestamp":1733764109000},"page":"104264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Kidney disease in multiple myeloma"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2005-8424","authenticated-orcid":false,"given":"Frank","family":"Bridoux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5542-6776","authenticated-orcid":false,"given":"Samih H.","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jaccard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7036-8423","authenticated-orcid":false,"given":"Virginie","family":"Royal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lpm.2024.104264_bib0001","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.kint.2020.11.010","article-title":"Management of acute kidney injury in symptomatic multiple myeloma","volume":"99","author":"Bridoux","year":"2021","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.lpm.2024.104264_bib0002","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.lpm.2024.104264_bib0003","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jnci\/djy167","article-title":"Acute kidney injury in patients receiving systemic treatment for cancer: a population-based cohort study","volume":"111","author":"Kitchlu","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.lpm.2024.104264_bib0004","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/ndt\/gfz211","article-title":"Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry","volume":"36","author":"Courant","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.lpm.2024.104264_bib0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3324\/haematol.2013.087585","article-title":"Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65\/GMMG-HD4 trial","volume":"99","author":"Scheid","year":"2014","journal-title":"Haematologica"},{"issue":"36","key":"10.1016\/j.lpm.2024.104264_bib0006","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1200\/JCO.2009.22.2232","article-title":"VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study","volume":"27","author":"Dimopoulos","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.lpm.2024.104264_bib0007","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1038\/bcj.2015.20","article-title":"Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma","volume":"5","author":"Gonsalves","year":"2015","journal-title":"Blood Cancer J"},{"issue":"17","key":"10.1016\/j.lpm.2024.104264_bib0008","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","article-title":"Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution","volume":"158","author":"Blad\u00e9","year":"1998","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.lpm.2024.104264_bib0009","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","article-title":"Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group","volume":"65","author":"Knudsen","year":"2000","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.lpm.2024.104264_bib0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1600-0609.1994.tb00190.x","article-title":"Renal function in newly diagnosed multiple myeloma\u2013a demographic study of 1353 patients. The Nordic Myeloma Study Group","volume":"53","author":"Knudsen","year":"1994","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.lpm.2024.104264_bib0011","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/ejh.12164","volume":"91","author":"Terpos","year":"2013","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.lpm.2024.104264_bib0012","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.lpm.2024.104264_bib0013","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.20.00298","article-title":"Randomized trial comparing double versus triple bortezomib-based regimen in patients with multiple myeloma and acute kidney injury due to cast nephropathy","volume":"38","author":"Bridoux","year":"2020","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.lpm.2024.104264_bib0014","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMra1810907","article-title":"Monoclonal gammopathy of renal significance","volume":"384","author":"Leung","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.lpm.2024.104264_bib0015","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","article-title":"Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications","volume":"132","author":"Fermand","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lpm.2024.104264_bib0016","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1016\/j.lpm.2024.104264_bib0017","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrneph.2018.8","article-title":"Animal models of monoclonal immunoglobulin-related renal diseases","volume":"14","author":"Sirac","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"10.1016\/j.lpm.2024.104264_bib0018","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1681\/ASN.2012060577","article-title":"Recurrent membranous nephropathy in an allograft caused by IgG3\u03ba targeting the PLA2 receptor","volume":"23","author":"Debiec","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.lpm.2024.104264_bib0019","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.ajkd.2004.09.029","article-title":"Recurrent Goodpasture's disease secondary to a monoclonal IgA1-kappa antibody autoreactive with the alpha1\/alpha2 chains of type IV collagen","volume":"45","author":"Borza","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.lpm.2024.104264_bib0020","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2016.09.045","article-title":"Thrombotic microangiopathy associated with monoclonal gammopathy","volume":"91","author":"Ravindran","year":"2017","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.lpm.2024.104264_bib0021","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/j.ajkd.2021.12.014","article-title":"Complement activation and thrombotic microangiopathy associated with monoclonal gammopathy: A national French case series","volume":"80","author":"Martins","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1016\/j.lpm.2024.104264_bib0022","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104264_bib0023","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.3389\/fimmu.2018.02260","article-title":"Both monoclonal and polyclonal immunoglobulin contingents mediate complement activation in monoclonal gammopathy associated-C3 glomerulopathy","volume":"9","author":"Chauvet","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.lpm.2024.104264_bib0024","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1053\/j.ajkd.2011.12.028","article-title":"Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies","volume":"59","author":"Nasr","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1016\/j.lpm.2024.104264_bib0025","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1681\/ASN.2012040388","article-title":"Mechanisms of light chain injury along the tubular nephron","volume":"23","author":"Sanders","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.lpm.2024.104264_bib0026","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/S0002-9440(10)64142-9","article-title":"Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein","volume":"158","author":"Ying","year":"2001","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.lpm.2024.104264_bib0027","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41408-020-0295-4","article-title":"Serum free light chain level at diagnosis in myeloma cast nephropathy-a multicentre study","volume":"10","author":"Yadav","year":"2020","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.lpm.2024.104264_bib0028","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood-2006-03-008953","article-title":"Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials","volume":"108","author":"Drayson","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.lpm.2024.104264_bib0029","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1172\/JCI115629","article-title":"Pathobiology of cast nephropathy from human Bence Jones proteins","volume":"89","author":"Sanders","year":"1992","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.lpm.2024.104264_bib0030","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1172\/JCI125517","article-title":"Immunoglobulin light chains generate proinflammatory and profibrotic kidney injury","volume":"129","author":"Ying","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.lpm.2024.104264_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1008449","article-title":"Understanding AL amyloidosis with a little help from in vivo models","volume":"13","author":"Martinez-Rivas","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.lpm.2024.104264_bib0032","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V98.3.714","article-title":"The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden","volume":"98","author":"Comenzo","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lpm.2024.104264_bib0033","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2011-05-355784","article-title":"The repertoire of \u03bb light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44","volume":"119","author":"Perfetti","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lpm.2024.104264_bib0034","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/blood-2018-09-872028","article-title":"Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study","volume":"133","author":"Joly","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lpm.2024.104264_bib0035","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00005792-200005000-00002","article-title":"Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients","volume":"79","author":"Messiaen","year":"2000","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.lpm.2024.104264_bib0036","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/ki.1995.269","article-title":"Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies","volume":"48","author":"Leboulleux","year":"1995","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.lpm.2024.104264_bib0037","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1681\/ASN.2015050581","article-title":"Impaired lysosomal function underlies monoclonal light chain-associated renal Fanconi syndrome","volume":"27","author":"Luciani","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2024.104264_bib0038","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2369-9-11","article-title":"Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure","volume":"9","author":"Hutchison","year":"2008","journal-title":"BMC Nephrol"},{"issue":"12","key":"10.1016\/j.lpm.2024.104264_bib0039","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2215\/CJN.11161111","article-title":"Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases","volume":"7","author":"Leung","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.lpm.2024.104264_bib0040","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1681\/ASN.2020010054","article-title":"Rate and predictors of finding monoclonal gammopathy of renal significance (MGRS) lesions on kidney biopsy in patients with monoclonal gammopathy","volume":"31","author":"Klomjit","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.lpm.2024.104264_bib0041","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/sj.ki.5001990","article-title":"Immunofluorescence on pronase-digested paraffin sections: a valuable salvage technique for renal biopsies","volume":"70","author":"Nasr","year":"2006","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.lpm.2024.104264_bib0042","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.kint.2021.02.038","article-title":"Immunofluorescence staining for immunoglobulin heavy chain\/light chain on kidney biopsies is a valuable ancillary technique for the diagnosis of monoclonal gammopathy-associated kidney diseases","volume":"100","author":"Nasr","year":"2021","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.lpm.2024.104264_bib0043","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2215\/CJN.07030712","article-title":"Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy","volume":"8","author":"Sethi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"21","key":"10.1016\/j.lpm.2024.104264_bib0044","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2017.17924","article-title":"Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial","volume":"318","author":"Bridoux","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.lpm.2024.104264_bib0045","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(19)30014-6","article-title":"High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial","volume":"6","author":"Hutchison","year":"2019","journal-title":"Lancet Haematol"},{"issue":"21","key":"10.1016\/j.lpm.2024.104264_bib0046","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood.2019003807","article-title":"Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study","volume":"135","author":"Royal","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.lpm.2024.104264_bib0047","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.ekir.2020.06.026","article-title":"Multiple myeloma-associated Ig light chain crystalline cast nephropathy","volume":"5","author":"Matsumura","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1016\/j.lpm.2024.104264_bib0048","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/modpathol.2017.124","article-title":"Intratubular amyloid in light chain cast nephropathy is a risk factor for systemic light chain amyloidosis","volume":"31","author":"Gibier","year":"2018","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.lpm.2024.104264_bib0049","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1681\/ASN.2015020185","article-title":"Light chain proximal tubulopathy: clinical and pathologic characteristics in the modern treatment era","volume":"27","author":"Stokes","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104264_bib0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/leu.2016.195","article-title":"Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients","volume":"31","author":"Vignon","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.lpm.2024.104264_bib0051","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/ndt\/gfq129","article-title":"Crystal-storing histiocytosis with renal Fanconi syndrome: pathological and molecular characteristics compared with classical myeloma-associated Fanconi syndrome","volume":"25","author":"El Hamel","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.lpm.2024.104264_bib0052","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.2010.30.5235","article-title":"Outcome in renal Al amyloidosis after chemotherapy","volume":"29","author":"Pinney","year":"2011","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.lpm.2024.104264_bib0053","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.lpm.2024.104264_bib0054","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1001\/jamaoncol.2024.2629","article-title":"Graded organ response and progression criteria for kidney immunoglobulin amyloidosis","volume":"10","author":"Muchtar","year":"2024","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.lpm.2024.104264_bib0055","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.kint.2022.03.030","article-title":"The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis","volume":"102","author":"Javaugue","year":"2022","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.lpm.2024.104264_bib0056","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.kint.2022.11.026","article-title":"Pathological characteristics of light chain crystalline podocytopathy","volume":"103","author":"Nasr","year":"2023","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.lpm.2024.104264_bib0057","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2215\/CJN.10491012","article-title":"Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases","volume":"8","author":"Said","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.lpm.2024.104264_bib0058","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1093\/ndt\/gfu242","article-title":"Misdiagnosing renal amyloidosis as minimal change disease","volume":"29","author":"Sayed","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.lpm.2024.104264_bib0059","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.kint.2019.05.027","article-title":"The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry","volume":"96","author":"Gonzalez Suarez","year":"2019","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.lpm.2024.104264_bib0060","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2215\/CJN.08640811","article-title":"Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution","volume":"7","author":"Nasr","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.lpm.2024.104264_bib0061","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.kint.2016.09.004","article-title":"Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management","volume":"91","author":"Bridoux","year":"2017","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.lpm.2024.104264_bib0062","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.ekir.2021.03.002","article-title":"Evidence for transition from light chain deposition disease by immunofluorescence-only to classic light chain deposition disease","volume":"6","author":"Nasr","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.lpm.2024.104264_bib0063","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.kint.2020.07.037","article-title":"Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants","volume":"99","author":"Nasr","year":"2021","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.lpm.2024.104264_bib0064","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.kint.2020.06.039","article-title":"Results of a nation-wide cohort study suggest favorable long-term outcomes of clone-targeted chemotherapy in immunotactoid glomerulopathy","volume":"99","author":"Javaugue","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.lpm.2024.104264_bib0065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1523-1755.2004.00365.x","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis","volume":"65","author":"Nasr","year":"2004","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.lpm.2024.104264_bib0066","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/ndt\/gfz176","article-title":"Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a nephrologist perspective","volume":"36","author":"Bridoux","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.lpm.2024.104264_bib0067","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.kint.2019.10.025","article-title":"Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone","volume":"97","author":"Nasr","year":"2020","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.lpm.2024.104264_bib0068","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1093\/ndt\/14.10.2370","article-title":"A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome","volume":"14","author":"Nakamoto","year":"1999","journal-title":"Nephrol Dial transplant"},{"issue":"11","key":"10.1016\/j.lpm.2024.104264_bib0069","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-020-00381-4","article-title":"Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients","volume":"10","author":"Fotiou","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.lpm.2024.104264_bib0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-023-00802-0","article-title":"Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy","volume":"13","author":"Moscvin","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.lpm.2024.104264_bib0071","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4103\/0973-1482.63570","article-title":"Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review","volume":"6","author":"Weide","year":"2010","journal-title":"J Cancer Res Ther"},{"issue":"6","key":"10.1016\/j.lpm.2024.104264_bib0072","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.2023.28239","article-title":"Severe hypocalcemia with denosumab among older female dialysis-dependent patients","volume":"331","author":"Bird","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.lpm.2024.104264_bib0073","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.lpm.2024.104264_bib0074","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.21873\/anticanres.11274","article-title":"High risk of tumor lysis syndrome in symptomatic patients with multiple myeloma with renal dysfunction treated with bortezomib","volume":"36","author":"Oiwa","year":"2016","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/j.lpm.2024.104264_bib0075","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/ndt\/gfv222","article-title":"Bortezomib-induced acute interstitial nephritis","volume":"30","author":"Cheungpasitporn","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1016\/j.lpm.2024.104264_bib0076","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1634\/theoncologist.2010-0070","article-title":"Lenalidomide-induced acute interstitial nephritis","volume":"15","author":"Lipson","year":"2010","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.lpm.2024.104264_bib0077","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1080\/10428194.2018.1515941","article-title":"Two cases of reversible Fanconi syndrome induced by lenalidomide","volume":"60","author":"Wesner","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.lpm.2024.104264_bib0078","first-page":"143","article-title":"Urinary obstruction due to extramedullary plasmacytoma: report of two cases","volume":"2","author":"Big\u00e9","year":"2009","journal-title":"NDT Plus"},{"issue":"5","key":"10.1016\/j.lpm.2024.104264_bib0079","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1053\/j.ajkd.2019.03.426","article-title":"Acute renal colic due to immunoglobulin free light chain kidney stones: a case report of an unusual complication of multiple myeloma","volume":"74","author":"Bouchet","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1016\/j.lpm.2024.104264_bib0080","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/ki.2008.108","article-title":"Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains","volume":"73","author":"Leung","year":"2008","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.lpm.2024.104264_bib0081","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1681\/ASN.2010080857","article-title":"Early reduction of serum-free light chains associates with renal recovery in myeloma kidney","volume":"22","author":"Hutchison","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.lpm.2024.104264_bib0082","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood-2018-06-860015","article-title":"Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR","volume":"133","author":"Dimopoulos","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lpm.2024.104264_bib0083","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11523-022-00897-8","article-title":"What's old is new: the past, present and future role of thalidomide in the modern-day management of multiple myeloma","volume":"17","author":"Costa","year":"2022","journal-title":"Target Oncol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104264_bib0084","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00280-016-3068-9","article-title":"Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment","volume":"78","author":"Bridoux","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"20","key":"10.1016\/j.lpm.2024.104264_bib0085","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2017.76.1742","article-title":"Pomalidomide plus low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma and renal impairment: results from a phase II trial","volume":"36","author":"Dimopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.lpm.2024.104264_bib0086","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"10192","key":"10.1016\/j.lpm.2024.104264_bib0087","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.lpm.2024.104264_bib0088","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"10292","key":"10.1016\/j.lpm.2024.104264_bib0089","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.lpm.2024.104264_bib0090","doi-asserted-by":"crossref","first-page":"e3293","DOI":"10.1002\/hon.3293","article-title":"Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy","volume":"42","author":"Dima","year":"2024","journal-title":"Hematol Oncol"},{"issue":"5","key":"10.1016\/j.lpm.2024.104264_bib0091","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1111\/bjh.16286","article-title":"Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study","volume":"190","author":"Cejalvo","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.lpm.2024.104264_bib0092","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.lpm.2024.104264_bib0093","doi-asserted-by":"crossref","first-page":"E322","DOI":"10.1002\/ajh.27063","article-title":"Teclistamab in patients with multiple myeloma and impaired renal function","volume":"98","author":"Joiner","year":"2023","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.lpm.2024.104264_bib0094","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1111\/bjh.19772","article-title":"Teclistamab for relapsed refractory multiple myeloma patients on dialysis","volume":"205","author":"Lebreton","year":"2024","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.lpm.2024.104264_bib0095","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-143-11-200512060-00005","article-title":"Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial","volume":"143","author":"Clark","year":"2005","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.lpm.2024.104264_bib0096","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2215\/CJN.06290615","article-title":"Trends in survival and renal recovery in patients with multiple myeloma or light-chain amyloidosis on chronic dialysis","volume":"11","author":"Decourt","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.lpm.2024.104264_bib0097","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1681\/ASN.2014090876","article-title":"ESRD due to multiple myeloma in the United States, 2001-2010","volume":"27","author":"Reule","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.lpm.2024.104264_bib0098","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ekir.2022.01.003","article-title":"Kidney transplant outcomes of patients with multiple myeloma","volume":"7","author":"Heybeli","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"8","key":"10.1016\/j.lpm.2024.104264_bib0099","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/sj.bmt.1704440","article-title":"Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant","volume":"33","author":"Lee","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.lpm.2024.104264_bib0100","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41409-019-0697-8","article-title":"Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras","volume":"55","author":"Li","year":"2020","journal-title":"Bone Marrow Transplant"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498224000435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498224000435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T23:46:37Z","timestamp":1741045597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498224000435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0755498224000435"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2024.104264","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney disease in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2024.104264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104264"}}